Burroughs Wellcome licenses Navelbine
Executive SummaryThe semi-synthetic vinca alkaloid vinorelbine from the French firm Pierre Fabre Medicament will be marketed in the U.S. and Canada by B-W under the agreement. The anticancer drug "has shown activity in non-small cell lung cancer and breast cancer in Phase II trials in Europe," the firm said. B-W expects to begin clinicals for lung and breast cancer in early 1990. Fabre has obtained in return certain rights to a future anticancer compound from Wellcome in Europe.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.